Text Size:  A  A
 

Vaginal Atrophy FAQ

If you still have questions about vaginal atrophy, you may find the answers below:

1. How common is vaginal dryness and painful intercourse associated with menopause?

Vaginal atrophy is very common in women experiencing menopause. If you experience vaginal atrophy, you may notice symptoms such as vaginal dryness, painful intercourse, irritation, soreness, itching, or burning during urination.

2. Why am I experiencing vaginal dryness?

Before a woman reaches menopause, her ovaries produce estrogen. One of the effects of estrogen is to maintain the thickness of the vaginal lining and stimulate vaginal secretions. At menopause the ovaries stop making estrogen. A decrease in estrogen levels results in a thinning of the walls of the vagina and a decrease in vaginal lubrication. These changes cause the symptoms of vaginal atrophy.

3. What is estrogen?

Estrogen is the family of hormones responsible for the development of the female reproductive system. Estradiol is the main estrogen found in women's bodies.

4. How do I know if I should see my healthcare provider?

Make an appointment to talk to your healthcare provider if you notice any uncomfortable or unusual symptoms, even if you're not sure if it's vaginal atrophy.

 


Vagifem® Indications and Usage

Vagifem® is used after menopause to treat menopausal changes in and around the vagina.

Vagifem® Important Safety Information

    What is the most important information I should know about VAGIFEM® (an estrogen hormone)   

  • Using estrogen-alone may increase your chance of getting cancer of the uterus (womb)
    Report any unusual vaginal bleeding right away while you are using Vagifem®. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find the cause.
  • Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline of brain function)
  • Using estrogen-alone may increase your chances of getting strokes or blood clots
  • Using estrogen-alone may increase your chance of getting dementia, based on a study of women age 65 years or older
  • Do not use estrogens with progestins to prevent heart disease, heart attack, or dementia
  • Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots
  • Using estrogens with progestin may increase your chance of getting dementia, based on a study of women 65 years and older
  • You and your healthcare provider should talk regularly about whether you still need treatment with Vagifem®

Do not start using Vagifem® if you currently have or have had certain cancers. Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. Also, do not start using Vagifem® if you have unusual vaginal bleeding, had a stroke or heart attack, currently have or have had blood clots, currently have or have had liver problems, are allergic to Vagifem® or any of its ingredients, or think you may be pregnant.

Vagifem® is only used in the vagina; however, the risks associated with oral estrogens should be taken into account.

The most commonly reported side effects of Vagifem® included: headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, and vaginal yeast infection.

Estrogens should be used at the lowest possible dose for your treatment only as long as needed.

Please click here for Prescribing Information and FDA-Approved Patient Labeling.

Vagifem® is only available by prescription. For more information about Vagifem®, please call 1-866-668-6336.
Novo Nordisk provides patient assistance for those who qualify. Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.



Vagifem® is a registered trademark of Novo Nordisk FemCare AG. © 2011 Novo Nordisk. All rights reserved. 0711-00004023-1 October 2011
To